Anonymous ID: 7cafd1 Oct. 10, 2021, 1:53 p.m. No.14760965   🗄️.is 🔗kun

>>14760249 LB

 

https://nypost.com/2021/10/10/tragic-georgia-plane-crash-kills-ceo-three-others/

 

F3 Platform Biologics Developing Cancer-Preventing Drugs …

 

[Search domain polsky.uchicago.edu] https://polsky.uchicago.edu/ › 2021 › 01 › 12 › f3-platform-biologics-developing-cancer-preventing-drugs-based-on-the-work-of-uchicago-researcher-david-grdina

 

F3 Platform Biologics is currently working with the Polsky Center for Entrepreneurship and Innovation's Science and Technology team to expand Grdina's patents for other uses on a global scale. "We have invested more than $4.5 million into the technology to get us where we want to go," said Jonathan Rosen, CEO and chairman of the company …

 

Polsky Center for Entrepreneurship and Innovation (https://polsky.uchicago.edu/)

 

Home - Polsky Center for Entrepreneurship and Innovation

 

https://polsky.uchicago.edu/2021/01/12/f3-platform-biologics-developing-cancer-preventing-drugs-based-on-the-work-of-uchicago-researcher-david-grdina/

 

F3 Platform Biologics is developing a low dose of the FDA-approved drug Amifostine. The solution helps prevent radiation-induced genomic damage and instability, which is a potential side effect of exposure to ionizing radiation, such as the radiation present in CT scans. (Image: iStock.com/Rabizo)

 

Amifostine has a long history and today could potentially help prevent the development of approximately 40,000 cancer cases each year – the goal of F3 Platform Biologics.

 

https://www.georgiacompanyregistry.com/companies/jonathan-d-rosen-family-foundation-inc/